natgillin/translations-raw huggingface dataset:
on the position to be adopted, on behalf of the European Union, within the EEA Joint Committee concerning an amendment to Annex II (Technical Regulations, Standards, Testing and Certification) and Annex XVII (Intellectual Property) to the EEA Agreement (Paediatric Regulation)
o stališču, ki se v imenu Evropske unije zavzame v Skupnem odboru EGP v zvezi s spremembo Priloge II (Tehnični predpisi, standardi, preskušanje in certificiranje) in Priloge XVII (Intelektualna lastnina) k Sporazumu EGP (Uredba o zdravilih za pediatrično uporabo)
Pursuant to Article 98 of the EEA Agreement, the EEA Joint Committee may decide to amend, inter alia, Annex II (Technical Regulations, Standards, Testing and Certification) and Annex XVII (Intellectual Property) to the EEA Agreement.
V skladu s členom 98 Sporazuma EGP se lahko Skupni odbor EGP med drugim odloči spremeniti Prilogo II (Tehnični predpisi, standardi, preskušanje in certificiranje) in Prilogo XVII (Intelektualna lastnina) k Sporazumu EGP.
Regulation (EC) No 1901/2006 of the European Parliament and of the Council [3] is to be incorporated into the EEA Agreement.
Uredbo (ES) št. 1901/2006 Evropskega parlamenta in Sveta [3] je treba vključiti v Sporazum EGP.
Regulation (EC) No 1902/2006 of the European Parliament and of the Council [4] is to be incorporated into the EEA Agreement.
Uredbo (ES) št. 1902/2006 Evropskega parlamenta in Sveta [4] je treba vključiti v Sporazum EGP.
Regulation (EC) No 469/2009 of the European Parliament and of the Council [5] is to be incorporated into the EEA Agreement.
Uredbo (ES) št. 469/2009 Evropskega parlamenta in Sveta [5] je treba vključiti v Sporazum EGP.
Commission Regulation (EU) No 488/2012 [6] is to be incorporated into the EEA Agreement.
Uredbo Komisije (EU) št. 488/2012 [6] je treba vključiti v Sporazum EGP.
Regulation (EC) No 469/2009 repeals Council Regulation (EEC) No 1768/92 [7], which has been incorporated into the EEA Agreement and which is therefore to be repealed under the EEA Agreement.
Uredba (ES) št. 469/2009 razveljavlja Uredbo Komisije (EGS) št. 1768/92 [7], ki je vključena v Sporazum EGP in jo je zato treba v okviru Sporazuma EGP razveljaviti.
Commission Regulation (EC) No 658/2007 [8] lays down rules concerning the application of financial penalties to the holders of marketing authorisations granted under Regulation (EC) No 726/2004.
Uredba Komisije (ES) št. 658/2007 [8] določa pravila o uporabi denarnih kazni za imetnike dovoljenj za promet, izdanih v skladu z Uredbo (ES) št. 726/2004.
Due to the special circumstances, namely, that the Commission grants marketing authorisations, that the infringements affect the Union and its interests, and the complex and technical nature of the infringement procedures, the EFTA Surveillance Authority should cooperate closely with the Commission and await the Commission's assessment and proposal for action before taking a decision regarding the application of financial penalties to the holders of marketing authorisations established in an EFTA State.
Zaradi posebnih okoliščin, zlasti da Komisija izdaja dovoljenja za promet, da kršitve vplivajo na Unijo in njene interese ter zaradi zapletene in tehnične narave postopkov za ugotavljanje kršitev, bi moral Nadzorni organ Efte tesno sodelovati s Komisijo ter počakati na oceno Komisije in predloge za ukrepanje, preden sprejme odločitev glede uporabe denarnih kazni za imetnike dovoljenj za promet s sedežem v državi Efte.
Annex II (Technical Regulations, Standards, Testing and Certification) and Annex XVII (Intellectual Property) to the EEA Agreement should therefore be amended accordingly.
Prilogo II (Tehnični predpisi, standardi, preskušanje in certificiranje) in Prilogo XVII (Intelektualna lastnina) k Sporazumu EGP bi bilo zato treba ustrezno spremeniti.
The position to be adopted, on behalf of the Union within the EEA Joint Committee, on the proposed amendment to Annex II (Technical Regulations, Standards, Testing and Certification) and Annex XVII (Intellectual Property) to the EEA Agreement, shall be based on the draft decision of the EEA Joint Committee attached to this Decision.
Stališče, ki se v imenu Unije zavzame v Skupnem odboru EGP glede predlagane spremembe Priloge II (Tehnični predpisi, standardi, preskušanje in certificiranje) in Priloge XVII (Intelektualna lastnina) k Sporazumu EGP, temelji na osnutku sklepa Skupnega odbora EGP, priloženega temu sklepu.
Done at Brussels, 27 March 2017.
V Bruslju, 27. marca 2017
Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (OJ L 378, 27.12.2006, p. 1).
Uredba (ES) št. 1901/2006 Evropskega parlamenta in Sveta z dne 12. decembra 2006 o zdravilih za pediatrično uporabo in spremembah Uredbe (EGS) št. 1768/92, Direktive 2001/20/ES, Direktive 2001/83/ES in Uredbe (ES) št. 726/2004 (UL L 378, 27.12.2006, str. 1).
Regulation (EC) No 1902/2006 of the European Parliament and of the Council of 20 December 2006 amending Regulation (EC) No 1901/2006 on medicinal products for paediatric use (OJ L 378, 27.12.2006, p. 20).
Uredba (ES) št. 1902/2006 Evropskega parlamenta in Sveta z dne 20. decembra 2006 o spremembah Uredbe (ES) št. 1901/2006 o zdravilih za pediatrično uporabo (UL L 378, 27.12.2006, str. 20).
Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (OJ L 152, 16.6.2009, p. 1).
Uredba (ES) št. 469/2009 Evropskega parlamenta in Sveta z dne 6. maja 2009 o dodatnem varstvenem certifikatu za zdravila, (UL L 152, 16.6.2009, str. 1).
Commission Regulation (EU) No 488/2012 of 8 June 2012 amending Commission Regulation (EC) No 658/2007 concerning financial penalties for infringement of certain obligations in connection with marketing authorisations granted under Regulation (EC) No 726/2004 of the European Parliament and of the Council (OJ L 150, 9.6.2012, p. 68).
Uredba Komisije (EU) št. 488/2012 z dne 8. junija 2012 o spremembi Uredbe Komisije (ES) št. 658/2007 o denarnih kaznih za kršitev nekaterih obveznosti v zvezi z dovoljenji za promet, izdanimi v skladu z Uredbo (ES) št. 726/2004 Evropskega parlamenta in Sveta (UL L 150, 9.6.2012, str. 68).
OJ L 182, 2.7.1992, p. 1.
UL L 182, 2.7.1992, str.
Commission Regulation (EC) No 658/2007 of 14 June 2007 concerning financial penalties for infringement of certain obligations in connection with marketing authorisations granted under Regulation (EC) No 726/2004 of the European Parliament and of the Council (OJ L 155, 15.6.2007, p. 10).
1.
DRAFT
Uredba Komisije (ES) št. 658/2007 z dne 14. junija 2007 o denarnih kaznih za kršitev nekaterih obveznosti v zvezi z dovoljenji za promet, izdanimi v skladu z Uredbo (ES) št. 726/2004 Evropskega parlamenta in Sveta (UL L 155, 15.6.2007, str. 10).
DECISION OF THE EEA JOINT COMMITTEE No …/2017
OSNUTEK
amending Annex II (Technical Regulations, Standards, Testing and Certification) and Annex XVII (Intellectual Property) to the EEA Agreement
SKLEP SKUPNEGA ODBORA EGP št. …/2017
THE EEA JOINT COMMITTEE,
o spremembi Priloge II (Tehnični predpisi, standardi, preskušanje in certificiranje) in Priloge XVII (Intelektualna lastnina) k Sporazumu EGP
Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 [1] is to be incorporated into the EEA Agreement.
ob upoštevanju Sporazuma o Evropskem gospodarskem prostoru (v nadaljnjem besedilu: Sporazum EGP) in zlasti člena 98 Sporazuma EGP,
Regulation (EC) No 1902/2006 of the European Parliament and of the Council of 20 December 2006 amending Regulation (EC) No 1901/2006 on medicinal products for paediatric use [2] is to be incorporated into the EEA Agreement.
Uredbo (ES) št. 1901/2006 Evropskega parlamenta in Sveta z dne 12. decembra 2006 o zdravilih za pediatrično uporabo in spremembah Uredbe (EGS) št. 1768/92, Direktive 2001/20/ES, Direktive 2001/83/ES in Uredbe (ES) št. 726/2004 [1] je treba vključiti v Sporazum EGP.
Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (Codified version) [3] is to be incorporated into the EEA Agreement.
Uredbo (ES) št. 1902/2006 Evropskega parlamenta in Sveta z dne 20. decembra 2006 o spremembah Uredbe 1901/2006 o zdravilih za pediatrično uporabo [2] je treba vključiti v Sporazum EGP.
Commission Regulation (EU) No 488/2012 of 8 June 2012 amending Commission Regulation (EC) No 658/2007 concerning financial penalties for infringement of certain obligations in connection with marketing authorisations granted under Regulation (EC) No 726/2004 of the European Parliament and of the Council [4], as corrected by OJ L 338, 12.12.2012, p. 44, is to be incorporated into the EEA Agreement.
Uredbo (ES) št. 469/2009 Evropskega parlamenta in Sveta z dne 6. maja 2009 o dodatnem varstvenem certifikatu za zdravila (Kodificirana različica) [3] je treba vključiti v Sporazum EGP.
Regulation (EC) No 469/2009 repeals Council Regulation (EEC) No 1768/92 [5], which has been incorporated into the EEA Agreement and which is therefore to be repealed under the EEA Agreement.
Uredbo Komisije (EU) št. 488/2012 z dne 8. junija 2012 o spremembi Uredbe Komisije (ES) št. 658/2007 o denarnih kaznih za kršitev nekaterih obveznosti v zvezi z dovoljenji za promet, izdanimi v skladu z Uredbo (ES) št. 726/2004 Evropskega parlamenta in Sveta [4], kakor je bila popravljena z UL L 338, 12.12.2012, str. 44, je treba vključiti v Sporazum EGP.
Commission Regulation (EC) No 658/2007 lays down rules concerning the application of financial penalties to the holders of marketing authorisations granted under Regulation (EC) No 726/2004.
Uredba (ES) št. 469/2009 razveljavlja Uredbo Komisije (EGS) št. 1768/92 [5], ki je vključena v Sporazum EGP in jo je zato treba v okviru Sporazuma EGP razveljaviti.
Due to the special circumstances, notably that the Commission grants marketing authorisations, that the infringements affect the Union and its interests and the complex and technical nature of the infringement procedures, the EFTA Surveillance Authority should cooperate closely with the Commission and await the Commission's assessment and proposal for action before taking a decision regarding financial penalties to the holders of marketing authorisations established in an EFTA State.
Uredba Komisije (ES) št. 658/2007 določa pravila o uporabi denarnih kazni za imetnike dovoljenj za promet, izdanih v skladu z Uredbo (ES) št. 726/2004.
Annexes II and XVII to the EEA Agreement should therefore be amended accordingly,
Zaradi posebnih okoliščin, in sicer zlasti da Komisija izdaja dovoljenja za promet, da kršitve vplivajo na Unijo in njene interese ter zapletene in tehnične lastnosti postopkov za ugotavljanje kršitev, bi moral Nadzorni organ Efte tesno sodelovati s Komisijo ter počakati na oceno Komisije in predloge za ukrepanje, preden sprejme odločitev glede denarnih kazni za imetnike dovoljenj za promet s sedežem v državi Efte.
Chapter XIII of Annex II to the EEA Agreement shall be amended as follows:
Prilogi II in XVII k Sporazumu EGP bi bilo zato treba ustrezno spremeniti –
The following text is inserted after the words ‘Committee on Orphan Medicinal Products (COMP)’ in the 13th paragraph of the introductory text:
Poglavje XIII Priloge II k Sporazumu EGP se spremeni:
‘, the Paediatric Committee’
za besede „Odbora za zdravila sirote (COMP)“ v 13. odstavku uvodnega besedila se vstavi naslednje besedilo:
The following indent is added in points 15q (Directive 2001/83/EC of the European Parliament and of the Council) and 15zb (Regulation (EC) No 726/2004 of the European Parliament and of the Council):
„Odbora za pediatrijo“;
32006 R 1901: Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 (OJ L 378, 27.12.2006, p. 1).’
v točkah 15q (Direktiva 2001/83/ES Evropskega parlamenta in Sveta) in 15zb (Uredba (ES) št. 726/2004 Evropskega parlamenta in Sveta) se doda naslednja alinea:
The adaptation text of point 15zb (Regulation (EC) No 726/2004 of the European Parliament and of the Council) is replaced by the following:
32006 R 1901: Uredba (ES) št. 1901/2006 Evropskega parlamenta in Sveta z dne 12. decembra 2006 (UL L 378, 27.12.2006, str. 1).“;
‘The powers vested in the European Commission in relation to the infringement procedure foreseen in Article 84(3), including the power to impose financial penalties on the holders of marketing authorisations, shall, in the cases where the marketing authorisation holder is established in an EFTA State, be carried out by the EFTA Surveillance Authority in close cooperation with the Commission.
besedilo prilagoditve točke 15zb (Uredba (ES) št. 726/2004 Evropskega parlamenta in Sveta) se nadomesti z naslednjim:
Before the EFTA Surveillance Authority takes a decision regarding financial penalties, the Commission shall provide it with its assessment and a proposal on how to act.’
„Pristojnosti, podeljene Evropski komisiji v zvezi s postopkom za ugotavljanje kršitev, določenim v členu 84(3), vključno s pristojnostjo za naložitev denarnih kazni imetnikom dovoljenj za promet, izvaja Nadzorni organ Efte v primerih, kadar ima imetnik dovoljenja za promet sedež v državi Efte, v tesnem sodelovanju s Komisijo.
The text of point 15zj (Commission Regulation (EC) No 658/2007) is replaced by the following:
Preden Nadzorni organ Efte sprejme odločitev glede denarnih kazni, mu Komisija predloži svojo oceno in predlog o tem, kako ukrepati.“;
‘32007 R 0658: Commission Regulation (EC) No 658/2007 of 14 June 2007 concerning financial penalties for infringement of certain obligations in connection with marketing authorisations granted under Regulation (EC) No 726/2004 of the European Parliament and of the Council (OJ L 155, 15.6.2007, p. 10), as amended by:
besedilo točke 15zj (Uredba Komisije (ES) št. 658/2007) se nadomesti z naslednjim:
32012 R 0488: Commission Regulation (EU) No 488/2012 of 8 June 2012 (OJ L 150, 9.6.2012, p. 68), as corrected by OJ L 338, 12.12.2012, p. 44.
„32007 R 0658: Uredba Komisije (ES) št. 658/2007 z dne 14. junija 2007 o denarnih kaznih za kršitev nekaterih obveznosti v zvezi z dovoljenji za promet, izdanimi v skladu z Uredbo (ES) št. 726/2004 Evropskega parlamenta in Sveta (UL L 155, 15.6.2007, str. 10), kakor je bila spremenjena z:
The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptation:
32012 R 0488: Uredbo Komisije (EU) št. 488/2012 z dne 8. junija 2012 (UL L 150, 9.6.2012, str. 68), kakor je bila popravljena z UL L 338, 12.12.2012, str. 44.
The powers vested in the European Commission in relation to the infringement procedure, including the power to impose financial penalties on the holders of marketing authorisations, shall, in the cases where the marketing authorisation holder is established in an EFTA State, be carried out by the EFTA Surveillance Authority in close cooperation with the Commission.
V tem sporazumu veljajo določbe Uredbe v skladu z naslednjimi prilagoditvami:
Before the EFTA Surveillance Authority takes a decision regarding financial penalties, the Commission shall provide it with its assessment and a proposal on how to act.’
Pristojnosti, podeljene Evropski komisiji v zvezi s postopkom za ugotavljanje kršitev, vključno s pristojnostjo za naložitev denarnih kazni imetnikom dovoljenj za promet, izvaja Nadzorni organ Efte v primerih, kadar ima imetnik dovoljenja za promet sedež v državi Efte, v tesnem sodelovanju s Komisijo.
The following point is inserted after point 15zo (Commission Implementing Regulation (EU) No 198/2013):
Preden Nadzorni organ Efte sprejme odločitev glede denarnih kazni, mu Komisija predloži svojo oceno in predlog o tem, kako ukrepati.“;
32006 R 1901: Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (OJ L 378, 27.12.2006, p. 1), as amended by:
za točko 15zo (Izvedbena uredba Komisije (EU) št. 198/2013) se vstavi naslednja točka:
32006 R 1902: Regulation (EC) No 1902/2006 of the European Parliament and of the Council of 20 December 2006 (OJ L 378, 27.12.2006, p. 20).
32006 R 1901: Uredba (ES) št. 1901/2006 Evropskega parlamenta in Sveta z dne 12. decembra 2006 o zdravilih za pediatrično uporabo in spremembah Uredbe (EGS) št. 1768/92, Direktive 2001/20/ES, Direktive 2001/83/ES in Uredbe (ES) št. 726/2004 (UL L 378, 27.12.2006, str. 1), kakor je bila spremenjena z:
The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptations:
32006 R 1902: Uredbo (ES) št. 1902/2006 Evropskega parlamenta in Sveta z dne 20. decembra 2006 (UL L 378, 27.12.2006, str. 20).
The application of Article 36(3) shall not be made dependent on an authorisation of the medicinal product in Liechtenstein.
V tem sporazumu veljajo določbe Uredbe v skladu z naslednjimi prilagoditvami:
The powers vested in the European Commission in relation to the infringement procedure foreseen in Article 49(3), including the power to impose financial penalties on the holders of marketing authorisations, shall, in the cases where the marketing authorisation holder is established in an EFTA State, be carried out by the EFTA Surveillance Authority in close cooperation with the Commission.
Uporaba člena 36(3) ne sme biti odvisna od odobritve zdravila v Lihtenštajnu.
Before the EFTA Surveillance Authority takes a decision regarding financial penalties, the Commission shall provide it with its assessment and a proposal on how to act.’.
Pristojnosti, podeljene Evropski komisiji v zvezi s postopkom za ugotavljanje kršitev, določenem v členu 49(3), vključno s pristojnostjo za naložitev denarnih kazni imetnikom dovoljenj za promet, izvaja Nadzorni organ Efte v primerih, kadar ima imetnik dovoljenja za promet sedež v državi Efte, v tesnem sodelovanju s Komisijo.
The text of point 6 (Council Regulation (EEC) No 1768/92) of Annex XVII to the EEA Agreement is replaced by the following:
Preden Nadzorni organ Efte sprejme odločitev glede denarnih kazni, mu Komisija predloži svojo oceno in predlog o tem, kako ukrepati.“
‘32009 R 0469: Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (Codified version) (OJ L 152, 16.6.2009, p. 1).
Besedilo točke 6 (Uredba Sveta (EGS) št. 1768/92) Priloge XVII k Sporazumu EGP se nadomesti z naslednjim:
The following paragraphs shall be added to Article 7:
„32009 R 0469: Uredba (ES) št. 469/2009 Evropskega parlamenta in Sveta z dne 6. maja 2009 o dodatnem varstvenem certifikatu za zdravila (Kodificirana različica) (UL L 152, 16.6.2009, str. 1).
Paragraph 5 shall not apply to the EFTA States.
v členu 7 se dodata naslednja odstavka:
Notwithstanding paragraph 4, for five years following the entry into force of Regulation (EC) No 1901/2006 in the EFTA State concerned, the application for an extension of the duration of a certificate already granted shall be lodged not later than six months before the expiry of the certificate.’;
Odstavek 5 se ne uporablja za države Efte.
The following paragraphs shall be added to Article 21:
Ne glede na odstavek 4 se pet let po začetku veljavnosti Uredbe (ES) št. 1901/2006 v zadevni državi Efte prijava za podaljšanje veljavnosti že izdanega certifikata vloži najpozneje šest mesecev pred iztekom veljavnosti certifikata.‘;
An application for an extension of the duration of a certificate can only be granted in an EFTA State where the certificate expires less than 6 months prior to the entry into force of Regulation (EC) No 1901/2006 in the EFTA state concerned.
v členu 21 se dodajo naslednji odstavki:
In cases where the certificate expires prior to the entry into force of Regulation (EC) No 1901/2006 in the EFTA state concerned, the extension shall take effect only with respect to the time following after both such entry into force in the EFTA state concerned and the date of the publication of the application for the extension.
Prijava za podaljšanje veljavnosti certifikata se lahko odobri samo v državi Efte, v kateri certifikat preneha manj kot 6 mesecev pred začetkom veljavnosti Uredbe (ES) št. 1901/2006 v zadevni državi Efte.
However, paragraph 3 of Article 13 shall apply as to the calculation of the duration of the extension.
Če certifikat v zadevni državi Efte preneha pred začetkom veljavnosti Uredbe (ES) št. 1901/2006, velja podaljšanje le za čas, ki sledi temu začetku veljavnosti v zadevni državi Efte ter datumu objave prijave za podaljšanje.
Notwithstanding paragraph 7 of Article 7, in cases where a certificate expires earlier than seven months after the entry into force of Regulation (EC) No 1901/2006 in the EFTA state concerned, the application for an extension of the duration of a certificate shall be lodged no later than one month after such entry into force in the EFTA state concerned.
Vendar se odstavek 3 člena 13 uporablja za izračun trajanja podaljšanja.
In these cases the extension takes effect only with respect to the time following the date of publication of the application for an extension.
Ne glede na odstavek 7 člena 7, kadar certifikat v zadevni državi Efte preneha prej kot sedem mesecev po začetku veljavnosti Uredbe (ES) št. 1901/2006, se prijava za podaljšanje veljavnosti certifikata vloži najpozneje mesec dni po tem začetku veljavnosti v zadevni državi Efte.
An application for an extension of the duration of a certificate lodged in accordance with paragraphs 3 and 4 shall not prevent any third party who, between the expiry of the certificate and the publication of the application for an extension of the duration of the certificate, in good faith has commercially used the invention or made serious preparation for such use, to continue such use.’;
V teh primerih podaljšanje velja le za čas, ki sledi datumu objave vloge za podaljšanje.
In view of the patent union between Liechtenstein and Switzerland, Liechtenstein shall not deliver any supplementary protection certificates for medicinal products as laid down in this Regulation.’.
Prijava za podaljšanje veljavnosti certifikata, ki je bila vložena v skladu z odstavkoma 3 in 4, ne preprečuje nobeni tretji osebi, ki je med prenehanjem certifikata in objavo prijave za podaljšanje veljavnosti certifikata izum v dobri veri komercialno uporabljala ali se na tako uporabo resno pripravljala, da tako rabo nadaljuje.‘;
Article 3
zaradi patentne unije Lihtenštajna in Švice Lihtenštajn ne izdaja dodatnih varstvenih certifikatov za zdravila, kot je navedeno v tej uredbi.“.
The texts of Regulations (EC) No 1901/2006, (EC) No 1902/2006, (EC) No 469/2009 and Commission Regulation (EU) No 488/2012, as corrected by OJ L 338, 12.12.2012, p. 44, in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the Official Journal of the European Union, shall be authentic.
Člen 3
Article 4
Besedila uredb (ES) št. 1901/2006, (ES) št. 1902/2006, (ES) št. 469/2009 in Uredbe Komisije (EU) št. 488/2012, kakor je bila popravljena z UL L 338, 12.12.2012, str. 44, v islandskem in norveškem jeziku, ki se objavijo v Dopolnilu EGP k Uradnemu listu Evropske unije, so verodostojna.
This Decision shall enter into force on …, provided that all the notifications under Article 103(1) of the EEA Agreement have been made [6].
Člen 4
Article 5
Ta sklep začne veljati … pod pogojem, da so bila predložena vsa uradna obvestila v skladu s členom 103(1) Sporazuma EGP [6].
The Secretaries to the EEA Joint Committee
Za Skupni odbor EGP
OJ L 378, 27.12.2006, p. 1.
Sekretarja Skupnega odbora EGP
OJ L 378, 27.12.2006, p. 20.
UL L 378, 27.12.2006, str.
OJ L 152, 16.6.2009, p. 1.
1.
OJ L 150, 9.6.2012, p. 68.
UL L 378, 27.12.2006, str.
Council Decision (CFSP) 2017/718
Sklep Sveta (SZVP) 2017/718